What is the Lacosamide?

Lacosamide is , while it's Molecular Formula is C 13 H 18 N 2 O 3 . A potent anticonvulsant.

What is the CAS number for Lacosamide?

The CAS number of Lacosamide is 175481-36-4.

What is Lacosamide (175481-36-4) used for?

Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation. It is effective in multiple rodent models of seizure activity. The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway. Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse. Lacosamide is regulated as a Schedule V compound in the United States.InChI:InChI=1/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

What is the Lacosamide?

Lacosamide is , while it's Molecular Formula is C 13 H 18 N 2 O 3 . A potent anticonvulsant.

What is the CAS number for Lacosamide?

The CAS number of Lacosamide is 175481-36-4.

What is Lacosamide (175481-36-4) used for?

Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation. It is effective in multiple rodent models of seizure activity. The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway. Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse. Lacosamide is regulated as a Schedule V compound in the United States.InChI:InChI=1/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

Product Class

175481-36-4

Product Name：Lacosamide
Molecular Formula：C₁₃H₁₈N₂O₃
Purity：99%
Molecular Weight：250.298

Inquiry

Product Details:

CasNo： 175481-36-4

Molecular Formula： C₁₃H₁₈N₂O₃

Chinese Factory Supply 99% Pure Lacosamide 175481-36-4 Safe Transportation

Molecular Formula:C₁₃H₁₈N₂O₃
Molecular Weight:250.298
Vapor Pressure:1.4E-11mmHg at 25°C
Melting Point:141-143?C
Refractive Index:1.52
Boiling Point:536.4 °C at 760 mmHg
PKA:14.19±0.46(Predicted)
Flash Point:278.2 °C
PSA：67.43000
Density:1.12 g/cm³
LogP:1.23570

Lacosamide(Cas 175481-36-4) Usage

Description	Lacosamide (LCM) is categorized as an anticonvulsant or antiepileptic drug (AED), specifically a third-generation anti-seizure medication. Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Huarong Pharm has successfully delivered innovative R&D products and services to more than 3,000 partners across the world. Our goal is to become a world-class leading company to support life science innovation and manufacturing.
Pharmacological Action	Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels without affecting the fast inactivation, thus stabilizing hyperexcitable neuronal membranes and reducing abnormal neuronal firing.
Uses	Lacosamide is a functionalized amino acid that reduces seizure activity in the brain by targeting the central nervous system (CNS). It is primarily used for treating partial-onset seizures and is also effective in treating primary generalized tonic-clonic seizures. It can be used as monotherapy or adjunctive therapy in conjunction with other antiepileptic medications. It is well absorbed following oral administration, has a bioavailability of approximately 100%, and is primarily eliminated via renal excretion.
Chemical Properties	White to Off-White Solid
Originator	Harris FRC (United States)
Brand name	Vimpat

InChI:InChI=1/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

175481-36-4 Relevant articles

Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial

Steve Chung, Michael R. Sperling, Victor Biton, Gregory Krauss, David Hebert, G. David Rudd, Pamela Doty, on behalf of the SP754 Study Group

, Epilepsia, Volume51, Issue6 June 2010 Pages 958-967

This multicenter, double-blind, placebo-controlled trial randomized patients 1:2:1 to placebo, lacosamide 400 mg, or lacosamide 600 mg/day. After an 8-week baseline period, patients began treatment with placebo or lacosamide 100 mg/day, were force-titrated weekly (100 mg/day increments) to the target dose, and entered a 12-week maintenance period.

Current understanding of the mechanism of action of the antiepileptic drug lacosamide

Michael A. Rogawski a, Azita Tofighy b, H. Steve White c, Alain Matagne d, Christian Wolff d

, Epilepsy Research Volume 110, February 2015, Pages 189-205

The antiepileptic drug lacosamide [(R)-2-acetamido-N-benzyl-3-methoxypropanamide], a chiral functionalized amino acid, was originally identified by virtue of activity in the mouse and rat maximal electroshock (MES) test. Attention was drawn to lacosamide because of its high oral potency and stereoselectivity.

Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications

Andreia Carona , Joana Bicker , Rui Silva , Carla Fonseca , Amílcar Falcão , Ana Fortuna

, Life Sciences Volume 275 , 15 June 2021, 119342

This review aims to describe the pharmacology, pharmacokinetics and clinical data of lacosamide, highlighting the characteristics that promote its potential to treat pathologies besides epilepsy. Moreover, it includes recent studies focusing the pharmacokinetics of lacosamide in several special populations, in order to identify the characteristics that should be considered to optimize patient treatment.

175481-36-4 Upstream products

171623-02-2
(R,S)-N-acetylserine-N-benzylamide
74-88-4
methyl iodide
58685-35-1
α-acetamido-N-benzyl-α-cyanoacetamide
175481-29-5
methyl α-acetamido-N-benzylmalonamate

175481-36-4 Downstream products

175481-36-4
(2S)-2-(acetylamino)-N-benzyl-3-methoxypropanamide
175481-36-4
lacosamide
262845-82-9
N-Benzyl-2-Amino-3-Methoxypropionamide
1318767-66-6
C₈H₇ClO₃*C₁₁H₁₆N₂O₂

Relevant Products

Apixaban
CAS：503612-47-3
Nemorexant
CAS：1505484-82-1
Tenofovir Disoproxil Fumarate
CAS：202138-50-9